ketolide

(redirected from Ketolides)
Also found in: Wikipedia.

ketolide

(kē-tō-līdz'),
Member of a class of antimicrobial agents related to macrolides.

ketolide

(kē′tō-līd″)
A derivative of the macrolide antibiotics, modified by the addition of a ketone to the macrolide structure. Telithromycin is a ketolide.
References in periodicals archive ?
Among the classes of antibiotics that act this way are macrolides, ketolides and the oxazolidinones that contribute more than $3 billion to the annual antibiotic marketplace.
Ketolides show great promise in fighting infections caused by increasingly important drug-resistant bacteria.
Central Daylight Time, Hall D Poster Session 176: Macrolides, Ketolides, Bicyclolides and Quinolones -- Poster E-1633: Assessment of In Vitro Activity of Cethromycin Against Telithromycin-resistant Strains of Streptococcus pneumoniae -- Poster E-1632: Assessment of In Vitro Activity of Cethromycin Against Strains of Streptococcus pneumoniae -- Poster E-1631: Assessment of In Vitro Activity of Cethromycin Against Strains of Haemophilus influenzae -- Poster E1634: Antimicrobial Activity of Cethromycin, a Novel Ketolide, Tested against a Diverse Collection of Francisella tularensis Strains Thursday, September 20, 9:00 a.
Ketek is the first in a new class of antibiotics known as ketolides.
Preclinical and Phase 1 clinical studies have shown an excellent pharmacokinetic profile for EDP-420, complementing an improved preclinical activity profile relative to currently marketed macrolides and ketolides, including against many strains of resistant S.
Preclinical studies have shown an excellent pharmacokinetic profile for EDP-420 (S-013420) and an improved activity profile relative to currently marketed macrolides and ketolides, including against many strains of resistant S.
Enanta's scientists have identified several novel ketolides that show potent antimicrobial activity against clinically relevant pathogens and are efficacious against resistant bacteria in animal infection models.
More recently, the ketolides (novel, semisynthetic, erythromycin-A derivatives) have demonstrated potent bactericidal activity against key respiratory pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Moraxella catarrhalis.
The second award received is a two-year Phase 2 SBIR grant totaling $1,191,248, which will support further development of novel semi-synthetic macrolides and ketolides as potential anti-microbial agents that may be active against resistant bacteria.
Ketolides, of which telithromycin is the first to be registered for clinical use, and quinupristin-dalfopristin are new compounds belonging to the macrolidelincosamide-streptogramin B (MLSb) class of antimicrobial agents.
Or's data identifies ketolides such as telithromycin and cethromycin, as promising new antimicrobial agents with the potential to treat respiratory tract infections caused by macrolide resistant organisms.